Investor Insight
Sirona Biochem is on track to commercialize its proprietary anti-aging product, increasing shareholder value and enhancing profitability.
Overview
Sirona Biochem (TSXV:SBM,FSE:ZSB,US OTC:SRBCF) is a biotechnology company with an innovative platform for developing safer, more effective cosmetic and therapeutic active ingredients. Sirona Biochem’s strategy involves bringing innovative patented compounds to market while also engaging in partnerships to license or sell them to prominent global enterprises. In exchange, receiving income generating sales, front-end fees, milestone payments, and ongoing royalties.
Sirona’s technology is based on proprietary carbohydrate chemistry developed by the company’s wholly-owned French subsidiary research and development (R&D) laboratory TFChem. This carbohydrate chemistry can improve the safety and efficacy of carbohydrate-based molecules, which have broad application potential for the development of therapeutics and cosmeceuticals. Examples of commercially available carbohydrate-based drugs include viral neuraminidase inhibitor Tamiflu, and Johnson & Johnson’s (NYSE:JNJ) SGLT2 inhibitor Invokana™.
The company has an exclusive global licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE:ABBV), to commercialize topical skin care treatments for dyschromia based on Sirona’s patents for TFC-1067 and related family of compounds. TFC-1067 is a very potent but safe dark spot remover and a breakthrough in the industry.
Sirona’s commercial launch of a serum containing our GlycoProteMim™ in 2025 is on track. The company’s Paris-based cosmetic branding expert has developed a compelling strategy to position this product as a premium offering in the anti-aging market highlighting GlycoProteMim's™ rejuvenating properties. GlycoProteMim™ serum will provide consumers with aging skin a breakthrough solution, delivering unmatched benefits without any observed adverse effects.
Sirona is led by a highly experienced team of biotechnology professionals. The company’s chief scientific officer Dr. Géraldine Deliencourt-Godefroy is an award-winning synthetic chemist and the founder of the French biotechnology company TFChem. Her scientific research in carbohydrate chemistry has led to the discovery of new drug families and the development of drug candidates for diabetes and obesity, cosmetic ingredients and biological adjuvants. She is the recipient of the acclaimed Francinov Research and Innovation Medal, the French Ministry of Research Award and the French Senate Award.
Technology Platform
Sirona’s technology platform is based on proprietary carbohydrate chemistry. Carbohydrate molecules play a central role in cell-to-cell communication and can interact with proteins, hormones, viruses, toxins and bacteria. In this way, carbohydrates perform a variety of essential biological functions in the human body, making them valuable components for the development of therapeutics and cosmeceuticals.
While they have broad application potential, carbohydrates are extremely challenging to develop due to their inherent instability. Using chemistry techniques originally developed by TFChem, Sirona has overcome the challenge of stabilizing carbohydrates to develop safer, more effective cosmetic and therapeutic active ingredients.
Sirona is exploring multiple commercial opportunities and partnerships for its carbohydrate technology platform and currently has two streams of product line: cosmetics and therapeutics.
Get access to more exclusive Pharmaceutical Investing Stock profiles here
Interactive Chart
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â